enGene Holdings Inc. (ENGN) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, enGene reported revenue of $0. Net income was -$117.3M, or $2.29 per diluted share. Operating activities generated -$99.2M of cash, leaving -$100.7M of free cash flow. At fiscal year end, enGene held $221.5M in total assets against $53.8M in total liabilities, including $50.2M of cash and equivalents.
Open the full interactive enGene financials → Quarterly statements, key ratios, valuation history and price charts.
enGene Key Stats
| Share Price | $1.63 |
|---|---|
| Market Cap | $113.7M |
| P/E Ratio | 0.7 |
| 52-Week Range | $1.44 – $12.17 |
| Shares Outstanding | 69.7 million (basic, 2026 Q3) |
enGene Income Statement
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Operating Income | -$26.1M | -$62.3M | -$123.2M |
| Pre-Tax Income | -$99.9M | -$55.2M | -$117.3M |
| Income Tax | $17,000 | -$19,000 | $0 |
| Net Income | -$99.9M | -$55.1M | -$117.3M |
| Diluted EPS | $151.22 | $1.46 | $2.29 |
enGene Quarterly Results
| 2025 Q4 | 2026 Q1 | 2026 Q2 | 2026 Q3 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$37.9M | -$29.8M | -$30.2M | -$32.5M |
| Diluted EPS | -$0.74 | $0.44 | -$0.43 | -$0.47 |
enGene Balance Sheet
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Cash & Equivalents | $81.5M | $173.0M | $50.2M |
| Current Assets | $85.4M | $247.4M | $201.4M |
| Total Assets | $87.0M | $311.2M | $221.5M |
| Current Liabilities | $5.3M | $14.7M | $32.0M |
| Total Long-Term Debt | $9.8M | $23.2M | $23.3M |
| Total Liabilities | $14.5M | $38.6M | $53.8M |
| Shareholders' Equity | $72.5M | $272.6M | $167.7M |
enGene Cash Flow Statement
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Cash From Operations | -$24.7M | -$48.3M | -$99.2M |
| Cash From Investing | -$318,000 | -$126.0M | -$25.1M |
| Cash From Financing | $86.1M | $265.7M | $1.5M |
| Free Cash Flow | -$25.0M | -$49.2M | -$100.7M |
| Dividends Paid | $0 | — | — |
Figures from enGene's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full enGene financials page for every line item.
enGene Company Profile
| Ticker | ENGN |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Saint-Laurent |
| Fiscal Year End | October 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company, emerging growth company |
| SEC CIK | 0001980845 |
Frequently Asked Questions
What was enGene's revenue in fiscal 2025?
enGene (ENGN) reported revenue of $0 for fiscal 2025.
What is enGene's annual revenue history?
enGene's annual revenue by fiscal year: 2023: $0; 2024: $0; 2025: $0.
What was enGene's net income in fiscal 2025?
enGene reported net income of -$117.3M for fiscal 2025.
What was enGene's earnings per share (EPS) in fiscal 2025?
enGene's diluted EPS was $2.29 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did enGene generate in fiscal 2025?
enGene generated -$100.7M of free cash flow in fiscal 2025.
What was enGene's revenue last quarter?
In its most recent reported quarter (2026 Q3), enGene reported revenue of $0.
How much debt does enGene have?
enGene reported $23.3M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of enGene are outstanding?
enGene reported a weighted average of 69.7 million basic shares outstanding in 2026 Q3.
What is enGene's market cap?
Based on its latest closing price, enGene (ENGN) has a market capitalization of about $113.7M.
When does enGene's fiscal year end?
enGene's fiscal year end, as registered with the SEC, is October 31.
Where is enGene headquartered?
enGene lists its business address in Saint-Laurent in its SEC filings.
enGene Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →